Movement Alert | Thermo Fisher Scientific Falls 3.12% in Regular Trading, Barclays Target Hike Triggers Profit Taking

Market Focus10-06 22:48

On October 6, Thermo Fisher Scientific declined 3.12% during regular trading, with the stock changing hands at approximately $655.66 per share and turnover surpassing $5.1 billion.

The move came despite Barclays raising its price target on the company to $750 from $650, reiterating an overweight rating, suggesting the decline primarily reflects profit-taking following a strong run-up rather than deteriorating fundamentals.

Supporting the long-term outlook, Thermo Fisher recently entered a study start-up agreement with Quantum BioPharma for a Phase 2 multiple sclerosis trial, expanding its clinical research pipeline. Earlier in the session, the stock had risen as much as 3% before reversing, while peers such as Illumina, Tempus AI, and Danaher traded lower, contributing to broader sector weakness in life sciences tools and services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment